Sean M. Clayton (858) 550-6034 sclayton@cooley.com | VIA EDGAR AND FEDERAL EXPRESS |
July 11, 2011
United States Securities and Exchange Commission | ||
Division of Corporate Finance | ||
Mail Stop 6010 | ||
100 F Street, N.E. | ||
Washington, D.C. 20549 | ||
Attn: | Jeffrey Riedler | |
Karen Ubell | ||
Re: | Horizon Pharma, Inc. | |
Registration Statement on Form S-1 (File No. 333-168504) | ||
Amendment No. 7 |
Dear Mr. Riedler and Ms. Ubell:
Enclosed for electronic filing via EDGAR pursuant to the Securities Act of 1933, as amended, on behalf of our client Horizon Pharma, Inc. (the“Company”), is Amendment No. 7 (“Amendment No. 7”) to the Company’s Registration Statement on Form S-1 (the“Registration Statement”) originally filed with the Securities and Exchange Commission (the“Commission”) on August 3, 2010. The copy of Amendment No. 7 that is enclosed with the paper copy of this letter is marked to show changes from the Registration Statement as filed on June 7, 2011.
Amendment No. 7 is being filed in response to comments received from the staff of the Commission (the“Staff”) by letter dated June 13, 2011 with respect to the Registration Statement and to reflect a 1 for 2.374 reverse stock split and preliminary price range. The revisions reflected in Amendment No. 7 include those provided supplementally to the Staff on June 30, 2011.
**********
Please advise us if we can provide any further information or assistance to facilitate your review. Please direct any further comments or questions regarding Amendment No. 7 or this response letter to me at (858) 550-6034 or Lynda Kay Chandler, Esq. at (858) 550-6014.
Sincerely,
Cooley LLP
/s/ Sean M. Clayton
Sean M. Clayton, Esq.
cc: | Timothy P. Walbert, Horizon Pharma, Inc. | |
Robert J. De Vaere, Horizon Pharma, Inc. | ||
Lynda Kay Chandler, Esq., Cooley LLP | ||
Barbara L. Borden, Esq., Cooley LLP | ||
Cheston J. Larson, Esq., Latham & Watkins LLP | ||
Divakar Gupta, Esq., Latham & Watkins LLP | ||
Matthew T. Bush, Esq., Latham & Watkins LLP |